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Short title: Desmoglein-3 epitope region peptides as synthetic antigens 
Abstract  
Oligopeptides, representing B- and/or T-cell epitope(s) are promising candidates as future 
synthetic antigens for studying human autoimmune disorders. Synthetic peptides could be as 
efficient in inducing in vitro T-cell responses as recombinant proteins. We have studied 
desmoglein 3 (Dsg3) peptides representing T-cell epitope regions to determine their capability 
to induce in vitro T-cell response and to analyze the influence of their solution conformation. 
The design of synthetic peptides used in this study was based on the previously described 
Dsg3 T-cell epitope regions and resulted in new N-terminally truncated versions. The peptides 
were prepared on solid phase and chemically characterized. In order to establish structure – 
activity relationship, the solution conformation of the synthetic peptides has been investigated 
using ECD spectroscopy. The in vitro T-cell stimulating efficacy as well as in vitro 
cytotoxicity and stability of the peptides have been determined on peripheral blood 
mononuclear cells (PBMC) isolated from whole blood of Pemphigus vulgaris (PV) patients 
and also from healthy donors. After 20 hours stimulation the IFN-γ content of the 
supernatants was measured by ELISA. Our data suggested that the in vitro IFN-γ production 
of PBMC culture derived from healthy donors and PV patients induced by synthetic peptides 
as antigens are markedly different. Comparative analysis of in vitro activity and the capability 
of oligopeptides to form ordered or unordered secondary structure was performed. We 
measured different in vitro T-cell stimulating activity on PBMC derived from patients and 
healthy donors, especially with synthetic peptides bearing high solvent sensibility which 
might suggest backbone flexibility. 
 
1. Introduction 
Desmogleins are cadherin type transmembrane adhesion proteins which form part of the core 
complex of desmosomes [1, 2]. These cell adhesion structures are present in large amount in 
tissues that are exposed to intense mechanical stress, including the epidermis and the heart 
muscle. Desmogleins are providing adhesion by the interaction with cadherins of the opposite 
cell. Inside the desmosome, these proteins are attached to the intercellular plaque proteins, 
e.g. desmoplakin, plakoglobin and plakophilin, which in turn interact with components of the 
cytoskeleton [3]. Therefore, desmosomes are essential for the integrity of the specific tissues. 
Desmoglein 3 (Dsg3), a member of the cadherin superfamily, is the main target of Pemphigus 
vulgaris (PV), a very rare but life-threatening autoimmune blistering disorder [4, 5]. This 
disease affects the skin and mucous membranes and is caused by autoantibodies binding to 
distinct sites of the extracellular part of Dsg3, leading to gradually diminished cell-cell 
adhesion [6-10]. The production of pathogenic autoantibodies is organic part of the 
development of PV, but several other immunological processes are required prior to 
autoantibody induction.  
Autoantigen specific T-cells play a crucial role in the initiation and progression of PV. 
Activation of autoreactive CD4+ T-cells depends on the autoantigen presentation by specific 
human leukocyte antigen (HLA) class-II alleles [11-15] expressed on antigen presenting cells 
(APC) such as dendritic cells, macrophages, and also B-cells. There is a positive feedback 
between B-cells and T-cells. Dsg3-specific T-cell response provides help to the B-cells to 
produce Dsg3-specific autoantibodies which bind to B-cell epitope regions [16, 17] of the 
Dsg3 protein antigen. 
The present, clinically applied PV diagnostics are based on autoantibody recognition of the 
recombinant Dsg3 antigen [18]. Characterization of the binding sites (B-cell epitope regions) 
of PV autoantibodies has been extensively studied [16-22]. Identification and detailed 
analysis of the immunodominant T-cell epitope regions of Dsg3 also have an impact in 
understanding the immunopathology and development of the disease and in the design of 
future peptide based synthetic antigens. CD4+ T-cells are also essential for induction of CD8+ 
cytotoxic T-cell (CTL) responses through both cytokine secretion and dendritic cell 
sensitization. Specific HLA class-I alleles appear to be also involved in PV which mediates 
natural killer cell (NK) as well as CD8+ CTL function [23].  
It is possible to determine T-cell epitope regions using synthetic peptides. Synthetic 
oligopeptides are as efficient in detecting in vitro T-cell responses as recombinant proteins. 
The benefit of using epitope peptides is that they do not require and probably do not go 
through uptake and processing, and can be presented directly by HLA class I and II molecules 
[24-26] via peptide loading and exchange catalyzed by a specific HLA class II molecule. 
HLA binding motifs with the use of peptide binding prediction methods (e.g. motif- and 
scoring matrix-based methods, artificial intelligence-based methods, structure-based methods) 
[27] may help in designing synthetic peptides, and in rationalizing their number. The fact that 
dominant epitopes frequently do not correspond to peptides which bind most tightly to HLA 
proteins [28] suggests that beside the appropriate amino acid composition for the binding 
motifs, the secondary structure can also affect the formation of ‘HLA – synthetic peptide’ 
complex and the recognition of this complex by the T-cell receptor.  
Precise analysis of the immunodominant epitopes is important for the better understanding of 
the disease, and for the development of new diagnostics. There are several advantages of 
using synthetic epitope peptides in in vitro stimulation studies. Synthetic oligopeptides 
corresponding to the epitope regions of the immunodominant protein are obviously smaller 
molecules (from dodecamer to heptadecamer (12-17mer) synthetic peptides vs. cca 600 
residues of the extracellular domain of the recombinant Dsg3 protein), therefore their 
production may be quicker, easier and more affordable, also the handling of the peptides is 
less problematic, e.g. the solubility and durability of the peptides is often better than that of 
larger molecules.  
Different synthetic techniques have been developed to analyze the immunodominant regions 
of proteins. Overlapping peptide libraries are useful tools for the identification of epitope 
regions. Small number of peptides can be synthesized manually or with synthesizer using 
solid phase techniques, and in case of a large number of peptides with Pepset technique [29]. 
Alanine scanning is a useful tool to identify individual amino acid residues responsible for the 
activity of the peptide [30]. With truncated peptide libraries equimolar mixtures of N- or C-
terminally truncated T-cell epitope peptide derivatives can be tested (e.g. 15-, 14-, 13- and 12-
mer derivatives of the original epitope). After screening, the elements of the positive mixtures 
can be tested separately to identify the shortest amino acid sequence needed for activity, 
resulting in the removal of the unnecessary residues while preserving the essential ones [30]. 
Alanine scanning is an effective approach also for studying the role of the flanking region 
amino acids [31].  
In some cases, the administration of oligopeptide epitopes does not elicit appropriate immune 
response [32]. In that case, to improve the immunogenicity of small peptides, the peptide 
sequence can be optimized by positional scanning, which means the substitution of an amino 
acid of interest with all other natural amino acids one at a time. Increase in activity identifies 
the preferred amino acid residues at the studied position [33].  
Although the mechanisms of CTL or helper T-cell induction by soluble antigens are not fully 
understood, features such as solubility, stability, and the conformation of the antigen, the 
affinity of binding to HLA class-I or -II molecules appear to be important for the induction of 
T-cell responses [34-36].  
Linear oligopeptides are expected to adopt multiple conformations in solution, in aqueous 
phase often unstructured, however, several studies to determine epitope regions using 
synthetic antigenic peptides assumed [35] or showed that the most potent T-cell and/or B-cell 
epitope peptides had tendency to form partially ordered structures in solution (authors applied 
various aqueous phases: water, PBS, 200 mM NaCl, water/TFE 9:1 v/v and non-aqueous 
phases: TFE, MeOH, ACN etc.) [36-40]. For instance in aqueous solution T-cell epitope 
peptides bearing β-turn structural elements [36] have been found besides the α-helical 
structure [37, 38] which was also found using the helix inducing solvent trifluoroethanol [39, 
40]. These observations are suggesting that besides the linear sequence of the synthetic 
peptide antigen, the conformational preference in solution is also important in binding to 
proteins. The adopted conformation of synthetic T-cell epitope peptides in aqueous solution 
and the impact of conformation on the peptides’ in vitro stimulating efficacy has not been 
studied widely.  
Several theoretical and experimental tools exist for the analysis of the conformation of 
peptides. Using in silico predictions (e.g. Chou-Fasman secondary structure prediction, 
Garnier – Osguthorpe – Robson method, neural network methods (PSIPRED, JPRED), 
support vector machines, sequence covariation methods, etc.) the preferred conformation of 
the synthetic peptide can be determined [36, 41-42]. Spectroscopic methods such as proton 
nuclear magnetic resonance (NMR), electronic circular dichroism (ECD) or Fourier transform 
infrared spectroscopy are applicable for the characterization of the conformational preferences 
of peptides in solution phase [36, 43-46]. All spectroscopic methods sample a collection of 
peptide conformations, including unfolded forms as well. Therefore, the spectra are the 
manifestation of the population-weighted average of the spectra characteristic for the 
individual contributing structures. 
The combination of in silico predictions, synthetic techniques and spectroscopic methods can 
be powerful tool for designing synthetic peptides as future antigens representing T-cell 
epitope regions.  
In the past, for nearly two decades, several attempts have been made to determine T-cell 
epitope regions of the Dsg3 protein using some, but not all of the aforementioned methods 
[47-50] (Table 1). Based on the HLA-DRβ1*0402 binding motif Wucherpfennig and 
colleagues identified seven peptides of the Dsg3 autoantigen [47] (Table 1). In their study in 
vitro T-cell response to the candidate peptides was evaluated using PBMC (peripheral blood 
mononuclear cells) originally isolated from peripheral blood of PV patients. From each 
patient, Dsg3/190-204 peptide/epitope specific T-cell lines were obtained. Two patients also 
showed response to peptide Dsg3/206-220, one patient responded to peptide Dsg3/251-265, 
and one to peptide Dsg3/762-776. T-cell response to peptides Dsg3/78-93, Dsg3/97-111 and 
Dsg3/512-526 has not been observed [47]. 
Lin et al. [48] identified T-cell response to three peptides (Dsg3/145-192, Dsg3/240-303, and 
Dsg3/570-614) representing stretches of the extracellular domain 1-5 of Dsg3 with the use of 
fusion proteins on the PBMCs of PV patients [48]. Hertl and coworkers [50] identified one 
immunodominant Dsg3 peptide (Dsg3/161-177; Table 1) by the stimulation of PBMCs of 
patients. They studied 17mer peptides staggered by five amino acid residues [49]. Riechers et 
al, identified the Dsg3/380-396 peptide as another immunodominant part of the Dsg3 protein 
(Table 1) [50].  
Moesta and coworkers [51] synthesized seven peptides and tested them for functional activity 
by proliferation assays using PBMC derived from PV patients. T-cell reactivity was detected 
to Dsg3/190-204, Dsg3/342-356, Dsg3/810-824 and Dsg3/963-974 peptides (Table 1). Their 
data, published as a conference abstract, also suggested that multiple epitopes may be 
operative in the autoimmune response in an individual patient [51, 63rd Annual Meeting of the 
Society for Investigative Dermatology, 2002, Los Angeles, CA, USA]. In the study of 
Veldman and coworkers Th1 and Th2 clones were established from PV patients and HLA-
matched healthy donors [52]. The 17mer peptides used in their assay were synthesized earlier 
with Pepset technique and contained acetylated N-terminus and diketopiperazine moiety at the 
C-terminus. [49]. All T-cell clones recognized the Dsg3/78-94, Dsg3/96-112, Dsg3/189-205, 
Dsg3/205-221 and Dsg3/250-266 peptides. Peptides Dsg3/96-112 and Dsg3/250-266 were 
recognized by the majority of T-cell clones from both patients and healthy donors. Peptides 
Dsg3/342-358 and Dsg3/376-392 were exclusively recognized only by T-cell clones from 
patients, while peptide Dsg3/483-499 was only recognized by T-cell clones from one healthy 
donor (Table 1) [52]. 
As this brief review of literature on this topic shows: i) PV is difficult to systematically study 
because of the relatively small number (4-16) of accessible donors [47-50, 52]. The 
difficulties are increased by stages of the disease in the different patients, different treatment, 
general condition of the patients, etc., ii) only few studies deal with structure – activity 
relationships using synthetic peptides as antigens [36-40], iii) there are no highly specific 
antigens related to T-cell epitope regions which could be selectively applied to distinguish in 
vitro T-cell response between healthy donors and PV patients [47-52], understandably, 
considering the different immunological, clinical status and HLA phenotype of the patients.  
Based on the literature data (Table 1) we synthesized 17mer (Dsg3/189-205 and Dsg3/342-
358 [49]) peptides and their N-terminally truncated derivatives according to the Dsg3 T-cell 
epitope regions (Table 2). In our present study regions Dsg3/206-220 and Dsg3/762-776 [47] 
were represented by two new 17mer peptides (Dsg3/206-222 and Dsg3/761-777). These are 
elongated versions of the already published synthetic peptides [47]. In case of Dsg3/762-776 
the elongation was necessary to avoid undesired side reactions on the peptide N- and C-
terminus. N-terminally truncated derivatives of these peptides were also prepared (Table 2). 
The peptides were chemically characterized. The secondary structure of the selected regions 
of Dsg3 was predicted with Chou-Fasman algorithm, and the conformation of the 17mer 
peptides and their truncated derivatives was studied in solution by electronic circular 
dichroism spectroscopy (ECD). Solubility was determined in cell culture medium (aqueous 
phase). The in vitro cytotoxicity was determined by colorimetric tetrazolium (MTT) assay 
prior to the in vitro T-cell stimulating experiments. PBMCs – isolated from whole blood 
samples of PV patients and healthy donors – were stimulated with the synthetic peptides, and 
the IFN-γ content of supernatants was determined by a two-MoAb sandwich ELISA system. 
A comparative analysis of these properties has to be carried out to prove the oligopeptides’ 
applicability as synthetic antigens. 
 2. Materials and Methods 
2.1. Chemicals and Reagents 
Solid phase peptide synthesis, analysis and purification 
All amino acid derivatives and resins were purchased from Iris Biotech GmBH 
(Marktredwitz, Germany). Coupling agents, cleavage reagents and scavengers (1-
hydroxybenzotriazole hydrate (HOBt), N,N′-diisopropylcarbodiimide (DIC), piperidine, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), trifluoroacetic acid (TFA), thioanizole, phenol, 1,2-
ethanedithiol (EDT) were obtained from Sigma-Aldrich Ltd (Budapest, Hungary). 1-Methyl-
2-pyrrolidon was obtained from Merck Ltd (Budapest, Hungary). N,N-Dimethylformamide 
(DMF), dichloromethane (DCM), diethylether and dimethylsulfoxide (DMSO) were 
purchased from Molar Chemicals Ltd (Budapest, Hungary). Hydrochloric acid (HCl), acetic 
acid, solvent for HPLC (acetonitrile (CH3CN)) and solvent for ECD (trifluoroethanol (TFE, 
NMR grade)) were purchased from Sigma-Aldrich Ltd (Budapest, Hungary).  
PBMC preparation, in vitro stimulation, MTT assay and ELISA 
RPMI-1640 medium, gentamicin and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) were obtained from Sigma-Aldrich Ltd (Budapest, Hungary). Fetal calf 
serum (FCS) was purchased from Biocenter Ltd (Szeged, Hungary). Ficoll® was purchased 
from Amersham Biosciences (Freiburg, Germany) and Staphylococcal Enterotoxin B (SEB) 
was obtained from Sigma-Aldrich Ltd (Budapest, Hungary). IFN-γ ELISA kit was purchased 
from BD (San Jose, CA, USA). Phosphate buffered saline (0.01 M PBS, pH=7.4) was 
prepared by dissolving 150 mmole NaCl, 8 mmole Na2HPO4×2H2O, 2.7 mmole KCl and 15 
mmole KH2PO4 (products of Sigma-Aldrich Ltd, Budapest, Hungary) in 1000 mL of 
deionized water. Tween-20 and o-phenylenediamine/H2O2 (SigmaFast) were also purchased 
from Sigma-Aldrich Ltd (Budapest, Hungary). 96-well U-bottom microtest plates and 96-well 
flat-bottomed plates were the products of Sarstedt Ltd (Budapest, Hungary), and Nunc 96-
well microtest plates were obtained from Sigma-Aldrich Ltd (Budapest, Hungary). 
2.2. Synthesis of Dsg3 T-cell Epitope Region Peptide Series 
Potential T-cell epitope peptides from the Dsg3 protein sequence and their N-terminally 
truncated derivatives (Table 2) have been synthesizedby solid phase peptide synthesis method 
using standard Fmoc/tBu chemistry on Rink Amide MBHA resin (nominal loading: 0.36 
mmole/g). We used tBu (Thr, Ser, Tyr), OtBu (Asp, Glu), Trt (Cys, His, Gln, Asn), Pbf (Arg) 
and Boc (Lys, Trp) as side chain protecting groups. The Fmoc α-amino protecting group was 
removed with 2% piperidine, 2% DBU/DMF (v/v) in 2+2+5+10 minutes. Then the resin was 
washed five times with DMF and twice with methanol. Coupling was performed with five 
equivalent of Fmoc-AA/DIC/HOBt 1:1:1 (n/n/n) in NMP for 60 min and monitored with 
ninhydrin test. After completing the synthesis, the peptides from the resin and the side chain 
protecting groups were removed with TFA/thioanisole/phenol/water/EDT 82.5:5:5:5:2.5 
(v/v/m/v/v) for 150 min. The crude products were lyophilized, then purified by RP-HPLC as 
described below, and the pure compounds were characterized by analytical RP-HPLC and 
ESI-MS. 
2.3. Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) 
The crude products were purified on a KNAUER 2501 HPLC system (KNAUER, Berlin, 
Germany) using a semipreparative Phenomenex Jupiter C18 column (250 mm x 10 mm) with 
10 µm silica (300 Å pore size; Gen-Lab Ltd., Budapest, Hungary). Linear gradient elution 
(10-75% B; 35 min) with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in 
acetonitrile/H2O (80:20, v/v)) was used at a flow rate of 4 mL/min. Peaks were detected at 
220 nm. Analytical RP-HPLC was performed on an Exformma EX1600 HPLC system (Gen-
Lab Ltd., Budapest, Hungary) using an Agilent Zorbax SB-C18 column (150 mm x 4.6 mm) 
with 5 µm silica, 80Å pore size (Kromat Ltd, Budapest, Hungary) as a stationary phase. 
Linear gradient elution (0-90% B; 20 min) with eluent A (0.1% TFA in water) and eluent B 
(0.1% TFA in acetonitrile/H2O (80:20, v/v)) was used at a flow rate of 1 mL/min. Peaks were 
detected at 220 nm.  
2.4. Mass Spectrometry (MS) 
Electrospray (ESI)-mass spectrometric analysis were carried out on an Esquire 3000+ ion trap 
mass spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were acquired in the 50 - 
2500 m/z range. Samples were dissolved in a mixture of 0.1% acetic acid in acetonitrile/H2O 
(50:50, v/v). 
2.5. Amino Acid Analysis  
Amino acid analysis was performed on Sykam Amino Acid S433H analyzer (Eresing, 
Germany) equipped with an ion exchange separation column and postcolumn derivatization. 
Prior to analysis the peptides were hydrolyzed with 6 M HCl in sealed and evacuated tubes at 
110°C for 24 h. For post-column derivatization the ninhydrin method was used.  
2.6. Secondary Structure Prediction Analysis of Dsg3 T-cell Epitope Regions 
The human Dsg3 (NCBI accession number: NP_001935.2, UniProt KB: P32926) sequence 
used for prediction was obtained from the protein sequence database [53, 54] 
[http://www.ncbi.nlm.nih.gov/protein (last accessed February 2015), 
http://www.uniprot.org/uniprot (last accessed February 2015)]. 
Secondary structure of the Dsg3 protein was predicted by the Chou–Fasman prediction 
method [55] using 7-amino acid windows in MicroSoft Excel applying the authors’ original 
matrices. The probability value of the predicted secondary structural element for each 
segment was plotted at the position of the fourth residue. Data presented in this article 
correspond to the Dsg3/189-205, Dsg3/206-222, Dsg3/342-358 and Dsg3/761-777 sequences, 
showing three additional residues on both N- and C-termini. 
2.7. Secondary Structure Determination of Dsg3 Peptides by Electronic Circular Dichroism 
(ECD) 
ECD spectra were recorded using a Jasco 810 polarimeter (Jasco Corporation, Japan) in the λ 
= 180-300 nm wavelength range using a 0.02 cm path length quartz cell at room temperature, 
under constant nitrogen flush with continuous scanning mode. All spectra reported here were 
obtained as an average of five individual scan and corrected with the solvent ECD spectra. 
The polarimeter was calibrated with ammonium α-10-camphor-sulfonate. The samples were 
dissolved in trifluoroethanol (TFE), distilled water and a 1:1 (V/V) mixture of TFE and 
distilled water. The solution concentration was in the range of 0.5-0.7 mg/mL for peptide 
amides. ECD band intensities are expressed in molar ellipticity ((θ)MR in deg cm2/dmol where 
MR = mean residue). The percentage of the different conformational elements contributing to 
the spectra was calculated by the Yang method [56].  
2.8. PV Patients and Healthy Donors 
Citrated/heparinated blood samples (14-18 mL) were obtained from three PV patients (Table 
3) who were seen at the Department of Dermato-Venereology and Skin Oncology, 
Semmelweis University (Budapest, Hungary) and from three healthy control donors. The 
number of ethical permission for this study is: TUKEB 74-75/1998. Patients have been 
characterized as Dsg3 positive according to the results of Mesacup Dsg-3 (MB-RG7685EC-
D) ELISA which contains recombinant protein antigen (MBL CO., LTD, Naka-ku, Nagoya, 
Japan). The clinical diagnosis of PV was confirmed by direct and indirect 
immunofluorescence microscopy. However, the patients were in slightly different stages of 
the disease with different symptoms. 
2.9. Stability Studies on the Synthetic Peptides in RPMI-1640 Cell Culture Medium 
Prior to in vitro studies the stability of the synthetic peptides were determined in serum-free 
RPMI-1640 medium. Peptides in 1 mg/mL concentration were incubated in the medium at 
37°C for 48 hours. Samples were analyzed with analytical RP-HPLC after 0, 24 and 48 hours 
of incubation using the KNAUER 2501 HPLC system (KNAUER, Berlin, Germany) with 
Phenomenex Jupiter C18 analytical column (250 mm x 4.6 mm, 5 µm silica, 300 Å pore size; 
Gen-Lab Ltd., Budapest, Hungary). Linear gradient elution (10-75% B; 35 min) with eluent A 
(0.1% TFA in water) and eluent B (0.1% TFA in acetonitrile/H2O (80:20, v/v)) was used at a 
flow rate of 1 mL/min. Peaks were detected at λ = 220 nm. 
2.10. Determination of the in vitro Cytotoxic Effect of the Peptides Using MTT Assay 
In vitro cytotoxic effect of the T-cell epitope region peptides was determined by MTT assay 
[57, 58]. PBMCs of a healthy control were divided into 96-well round-bottomed plate in 100 
µL RPMI-1640 culture medium with an initial cell number of 2×105 cells/well. After 
overnight incubation of the cells (37°C) the peptides were dissolved in fresh culture medium 
and were added to the cells at 0.5, 5.0, 50, and 500 µM concentrations. After overnight 
incubation at 37°C, cells were washed twice with serum-free medium, then the cell viability 
was determined by MTT assay using 45 µL of MTT solution (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, c = 2.0 mg/mL) in each well. The respiratory chain [57, 58] 
and other electron transport systems of the living cell reduce MTT and thereby form non-
water-soluble violet formazan crystals within the cell; the amount of the formazan crystals can 
be determined spectrophotometrically. After 4.5 h incubation, cells were centrifuged for 5 min 
at 900 g, than the supernatant was removed. Crystals were dissolved in DMSO, and the 
optical density (OD) of the samples was measured with iEMS MF ELISA reader (Labsystem, 
Helsinki, Finland) at λ = 540 nm, and λ = 620 nm as reference wavelength. The percent of 
cytotoxicity was calculated using the following equation:  
Cytotoxicity% = [1-(ODtreated / ODcontrol)] × 100, 
where ODtreated and ODcontrol correspond to the optical densities of treated and control cells, 
respectively. Cytotoxicity% was plotted as a function of concentration fitted to a sigmoidal 
curve and the 50% inhibitory concentration (IC50) value was determined from these curves. 
2.11. In vitro Stimulation of PBMC with Dsg3 T-cell Epitope Region Peptides 
PBMC were isolated from the whole blood of the donors as described [59]. Whole 
citrated/heparinated blood, diluted 1:2 (v/v) in RPMI-1640 incomplete media (ICM), was 
centrifuged on the Ficoll density gradient [59]. PBMC were washed in ICM twice and then 
resuspended in RPMI-1640 supplemented with 10% fetal calf serum (FCS). PBMC were 
cultured at 2×105/well in 96-well round-bottomed plates. Peptides (freshly dissolved in ICM) 
were added to the cells at concentrations 25 µM. The IFN-γ concentration determined from 
the supernatant of PBMC stimulated by RPMI-1640 medium was considered as untreated 
(negative) control. As nonspecific positive control, SEB was used at 5 µg/mL concentration. 
After 20 hours of incubation, supernatants were harvested and stored at - 80 °C until use. IFN-
γ content was measured by sandwich ELISA [60]. 
2.12. Determination of IFN-γ Concentration from PBMC Supernatants 
Supernatant from treated PBMC was tested for IFN-γ content. For this, a two-MoAb 
sandwich ELISA (Enzyme Linked Immunosorbent Assay) kit was used in accordance with 
the recommendation of the manufacturer [60]. As capture antibody human anti-IFN-γ (BD 
551221) was used. The IFN-γ concentration (pg/mL) of PBMC supernatant was determined 
using biotinylated mouse anti-IFN-γ (BD 554550) as detection antibody. After washing with 
0.01 M PBS-Tween-20 (5×5 min) the color reaction was developed with o-
phenylenediamine/H2O2 dissolved in deionized water and measured on iEMS MF ELISA 
reader (Labsystem, Helsinki, Finland) at λ = 492 nm and λ = 620 nm. The IFN-γ 
concentration was calculated with reference to the standard curve. Detection limit was 1 
pg/mL for IFN-γ. 
3. Results and Discussion 
 
We have designed, synthesized and structurally characterized Dsg3 peptides representing four 
T-cell epitope regions (189-205 [49], 206-220 [47], 342-358 [49], 762-776 [47]) published 
previously in the literature. Dsg3/206-220 and Dsg3/762-776 were elongated by two amino 
acids based on the Dsg3 protein sequence to form the 17mer Dsg3/206-222 and Dsg3/761-
777. In case of Dsg3/762-776 the elongation was necessary to avoid undesired side reactions 
on the peptide N- and C-terminus. In addition, N-terminally truncated versions of all four 
epitope region peptides were prepared and chemically characterized (Table 2). The solubility, 
secondary structure in solution, as well as in vitro cytotoxicity of the peptides were 
determined. The in vitro T-cell stimulatory activity of these compounds was evaluated on 
PBMC isolated from healthy donors and PV patients. Comparative analysis was performed 
regarding the applicability of the oligopeptides as synthetic antigens.  
 
3.1. Synthesis and Chemical Characterization of T-cell Epitope Peptide Series 
All peptides were synthesized with Fmoc/tBu solid phase method using Rink Amide MBHA 
resin resulting in peptide amide N-terminus. After TFA cleavage, the crude products were 
purified by RP-HPLC. The characterization of the peptides by mass spectrometry and amino 
acid analysis confirmed the expected composition (Table 2).  
 
3.2. Secondary Structure Prediction Analysis of Dsg3 T-cell Epitope Regions 
In order to correlate solution conformation with in vitro biological activity, we have 
performed secondary structure prediction analysis of the Dsg3 regions corresponding to the 
189-205, 206-222, 342-358, and 761-777 regions by Chou-Fasman approach [55].  
According to the prediction analysis data Dsg3 region 189-205 has a propensity to form a β-
strand in the middle of the sequence (194-199), flanked by probable β-turns on both termini 
(Figure 1A). The Dsg3 region 206-222 has a slight preference for ordered, mostly β-strand 
structure broken with a β-turn in the middle of the sequence (Figure 1B), but the differences 
between the different conformational elements are small. Prediction analysis of 342-358 
region shows that the N-terminal of the sequence may adopt β-strand or with lower 
probability α-helix conformation, while its C-terminus is probably in α-helical structure, 
according to the 7 residue long stretch (349-355) showing strong preference for this structure 
(Figure 1C). 761-777 region is most probably involved in forming several β-turn structures in 
the length of this sequence with unordered structure around residue 767 (Figure 1D). 
3.3. Secondary Structure Determination of Dsg3 Peptides by Electronic Circular Dichroism  
In order to validate the results of prediction analysis we have made an effort to determine 
experimentally the solution conformation of peptides described above by using ECD 
spectroscopy.  
The secondary structures of peptides and proteins in solution can be determined with ECD 
spectroscopy. In solution the measured ECD curve is the sum of ECD of the different 
conformers. ECD spectra of the different secondary structures (ordered as periodic and 
aperiodic; and unordered conformations) are welldocumented. The ECD study of the peptides 
in water and TFE (α-helix promoting and membrane mimicking solvent) can help 
understanding the conformational stability and the solvent-sensitivity of peptides [75, 76]; in 
addition, it can be useful at structure – function investigations. 
The ECD curve of the α-helix has a broad negative band at λ ~ 222 nm (n-pi* transition), a 
negative band at λ ~ 208 nm and a very intense positive band at λ ~ 192 nm (exciton couplet, 
pi-pi*) [61, 62]. ECD spectrum of a β-sheet has a negative band at λ ~ 215 nm (n-pi* transition) 
with weaker intensity and a positive band at 195-200 nm (pi-pi* transition). Different turn-
types can also be detected and distinguished by their characteristic chiral contributions. The 
ECD spectrum of a type I or III β-turn is similar to the α-helix spectrum (class C spectrum), 
but the band intensities are weaker, the pi-pi* bands are blue-shifted, while the n-pi* bands are 
red-shifted [63]. Type II β-turns have similarity to the β-sheet spectrum, but the bands are red-
shifted by 5-10 nm, and an inverse γ-turn structure is characterized by a similar ECD shape 
[64]. ECD spectrum with an intensive negative band around λ ~ 200 nm and with a weak 
negative shoulder near λ ~ 230 nm can be interpreted as a random coil (U-type ECD shape). 
Similar spectral features but with a weak positive shoulder at ~230 nm can be identified as 
polyproline type II helix (PPII) [65, 66]. 
The conformation of Dsg3/189-205, Dsg3/206-222, Dsg3/342-358, and Dsg3/761-777 full 
length peptides and their truncated derivatives was characterized by ECD spectra recorded in 
TFE, water, and water/TFE mixture 1:1 (v/v) which solvents mimic the hydrogen bond 
stabilizing and destabilizing environments, respectively. ECD data are presented in Figure 2 
and Table 4, 5, and in the Supplementary Figure S1-S5 and Table S1. Changes in the spectra 
in different solvents can give information about the solvent-sensitivity and the conformational 
preference of the peptides. First we will summarize the spectroscopic features of the full 
length peptides, followed by the description of the truncated derivatives.  
The ECD spectra of all full length peptides in TFE (Figure 2A) show a positive and a negative 
pi-pi* band pair around λ ~ 190 nm and 206-208 nm, and an n-pi* broad band centralized 
around λ ~ 222 nm, indicating the presence of ordered, helical structure, mainly α-helix. The 
location and the similarity of band intensities show that there is only a small difference 
between the conformer population of Dsg3/206-222 and Dsg3/342-358 peptides. Both 
peptides show highly ordered structures in TFE (the α-helix content is more than 50%). In 
case of Dsg3/189-205 and Dsg3/761-777 peptides the intensity of all bands are much smaller; 
so the ratio of ordered to unordered structures is smaller (α-helix content is only 
approximately 30%). The two unequal negative ECD bands of the peptide Dsg3/189-205 
suggest the presence of 310 helix as well (Figure 2A). Wavelength and intensity of band 
extrema, and intensity ratio of the negative pi- pi* and the n- pi* bands are shown in Table 4.  
ECD spectra of Dsg3/189-205, Dsg3/206-222 and Dsg3/342-358 peptides in water/TFE (1:1, 
v/v) solvent mixture (Table 4, Figure S1) can be characterized by a positive and a negative pi-
pi* band at λ ~ 190 nm and λ ~ 205 nm, and a broad negative band (n-pi*) centralized at λ ~ 
220 nm. All bands have smaller intensities than in TFE indicating less α-helix content. The 
changed ratio of bands at λ ~ 220 nm and λ ~ 205 nm suggests the appearance of shorter 
helical structures as 310 helices in the conformer mixture [67-68]. Besides the helical 
structures, unordered and shorter ordered units (turns) can be observed. In case of Dsg3/761-
777 peptide the ECD curve main features are the following: weak positive band (λ ~ 183 nm), 
stronger negative pi-pi* band at λ = 199 nm, and a weak but broad negative n-pi* band 
(centralized at λ = 228 nm). This shape indicates the presence of unordered/PPII as dominant 
structure. These data emphasize that the secondary structures of the first three 17mer peptides 
are caused not only by the structure-inducing effect of the TFE, their ordered structure is 
relatively stable (their “solvent resistance” is higher than that of the fourth peptide).  
The ECD spectra of the peptides in water (Figure 2B, Table 4) show a broad and intensive 
negative band at λ ~ 200 nm with a weak negative shoulder at λ ~ 225-230 nm, this can be 
interpreted mainly as unordered/PPII structure. In case of the Dsg3/206-222 and Dsg3/761-
777 peptides, the intensity of the band at λ ~ 198 nm is weaker than in case of the Dsg3/189-
205 and Dsg3/342-358 peptides. The types of secondary structure elements in the Dsg3/189-
205 and Dsg3/342-358 peptides resemble mainly unordered/ PPII helix structure. 
During the secondary structure evaluation of the N-terminally truncated derivatives of 
Dsg3/189-205 peptide (namely, Dsg3/190-205, Dsg3/192-205) we have observed no 
significant differences in TFE compared to the full length Dsg3/189-205 peptide. The ECD 
curves indicated the presence of ordered, helical structure, mainly α-helix (~ 30%) with 
unordered and β-sheet structures besides. On the other hand, based on the shape and the lower 
intensities of the ECD curve of Dsg3/194-205 peptide, probably the dominant secondary 
structure is the 310 helix (and/or βI(III) turn) and β-sheet conformation apart from the 
unordered structure. The significantly lower band intensities and the calculated low α-helix 
(~5%) content of Dsg3/194-205 peptide suggest a higher ratio of β-sheet/β-turn and unordered 
structures (Table S1, Figure S2A). 
In 50 % TFE-water solvent mixture ECD spectra were characterized by lower intensity bands 
and the blue-shifted band at λmax = 206 nm. These features indicate that in the conformer 
population unordered structural elements are present in a higher ratio, but the helical features 
of the spectra are also preserved (Table S1, Figure S2B). These data suggest that the solvent 
resistance of these peptides is relatively high; in the 50% solvent still the ordered structure 
dominates. All truncated peptides show the same ECD spectrum in water (a strong negative 
band at 195-200 nm which is accompanied by a shoulder at λ ~ 230 nm), which reflects their 
unordered structure (Table S1, Figure S2C). The ECD results in TFE are in good agreement 
with the Chou-Fasman prediction, which shows mainly β-structures (β-sheet and isolated β-
turns) (Figure 1A). 
In TFE and 50% TFE/water mixture the conformer population of the truncated derivatives of 
Dsg3/206-222 and Dsg3/342-358 peptides are very similar: mainly α-helices (in TFE ~60% 
and ~50%) (Table S1; Figure S3A, S4A). However, analyzing the spectra of the shortest 
peptide from the Dsg3/342-358 series (Dsg3/347-358) the low intensity bands and the C-type 
ECD shape indicate the presence of mainly β-turns (probably βI(III) turns) apart from 
unordered conformational elements. 
In 50% TFE/water 1:1 v/v as solvent the ratio of the unordered conformers has increased 
(Table S1, FigureS3B, S4B) as expected. In water Dsg3/206-222 peptide series shows a 
typical U-type ECD shape which indicates that mostly the unordered structures dominate. 
(Table S1, FigureS3C, S4C). Peptide series Dsg3/342-358 shows similar features, but the 
weak negative band at λ ~ 225 nm red shifted compared to the full length peptide. In case of 
Dsg3/342-358 peptide the band intensity at λ ~ 200 nm significantly decreased. Based on the 
results of Shanmugam and Polaravapu [77], this type of spectrum shows a significant 
contribution of PPII-type conformation (a mixture of unordered and PPII conformations). 
According to the prediction data in both peptide series periodical ordered structure dominates. 
Next the Dsg3/761-777 series was analyzed. In TFE the truncated derivatives of Dsg3/761-
777 full length peptide show lower intensity ECD spectra, compared to the intensity of the 
spectra of other peptide series. This fact indicates lower helical content of the conformer 
population: mainly α-helical structure was observed besides unordered structure elements 
(Table 5, Figure 2C). The shortest Dsg3/766-777 peptide shows typical C-type curve 
reflecting the presence of β-turn conformers (β-I(III) besides unordered structures. In TFE-
water mixture all peptides from this series have U-type ECD curves with low intensity (Table 
5, Figure 2D) and weaker negative bands at 225-231 nm. The higher ratio of unordered 
conformers besides ordered conformers (mainly turns) indicates higher backbone flexibility.  
The unordered structure ratio is much higher compared to any other peptide series (Table 5, 
Figure 2D), showing very high solvent sensitivity and the instability of the ordered structural 
elements. As demonstrated on Figure 2 B and D, the ECD curves of the truncated series of 
Dsg3/761-777 peptide recorded in TFE-water mixture are very similar to the ECD curves of 
all the other peptide series in water (Figure S2C, S3C, S4C, S5, Table 4, 5, S1).  
These findings suggesting the presence of isolated turns are in good agreement with the Chou-
Fasman analysis, which showed very high probability of turn structures for the Dsg3/761-777 
region.  
 
3.4. In vitro PBMC Stimulating Activity of T-cell Epitope Region Peptide Series; IFN-γ 
Production 
Prior to stimulation experiments the stability and in vitro cytotoxicity of the synthetic peptides 
were analyzed. In the RPMI-1640 cell culture media Dsg3/206-222, Dsg3/342-358, 
Dsg3/343-358 and Dsg3/345-358 peptides required five minutes sonication for complete 
solubilization. The stability of the synthetic peptides was analyzed with RP-HPLC after 0, 24 
and 48 hours of incubation in RPMI-1640 medium at 37°C. All peptides were stable at these 
conditions for 48 hours. As an example, analytical RP-HPLC chromatograms corresponding 
to the RPMI-1640 medium and the Dsg3/761-777 peptide after 0, 24 and 48 hours of 
incubation presented in Figure 3 show that the peptide remains intact under these conditions, 
for the other peptides data are not shown. 
The in vitro cytotoxic effect of the 17mer peptides and their N-terminally truncated 
derivatives on PBMC cells isolated from healthy blood donors was studied at various 
concentrations (0.5, 5.0, 50, and 500 µM) using MTT assay. Data are summarized in Table 2. 
Dsg3/342-358 and Dsg3/345-358 peptides have shown cytotoxicity in vitro at 252 µM and 
290 µM IC50 value, respectively. The other peptides had no cytotoxic effect in vitro even at 
the highest concentration (500 µM) after overnight incubation.  
PBMCs isolated from three PV patients (Table 3) and three healthy donors (gender and age of 
the donors: D1: ♀ (female), 44y; D2: ♂ (male), 59y; D3: ♀, 28y) were stimulated with the 
synthetic peptides in two parallels, using 25 µM peptide concentrations for 20 h. After 
stimulation, supernatants were collected and the IFN-γ concentration was measured with a 
two-MoAb sandwich ELISA. The IFN-γ concentration determined from supernatant of 
PBMC stimulated by the culture medium was considered as negative (untreated) control. As 
nonspecific positive stimulating control, SEB was used (data not shown). 
The selected threshold (average IFN-γ concentration from supernatant of unstimulated PBMC 
of healthy donors) was 50 pg/mL IFN-γ (± 25 pg/mL) (Figure 4). We represented an average 
IFN-γ concentration (at least two parallel measurements) from PBMC cultures of patients and 
healthy donors. Usually the ELISA measurements resulted in less than 25 % standard 
deviation (SD) regarding the IFN-γ levels. Approximately in one third of the cases we faced 
higher standard deviation than 25%, which SD can occur using supernatants for IFN-γ 
determination, as we experienced earlier [39]. We created a set of conditions (the threshold 
value for normal IFN-γ level generated from healthy donor untreated concentration; managing 
the SD values with graphical emphasis) to allow representation of all ELISA data for the 
peptide series (Figure 4A patients, Figure 4B healthy donors).  
There is a marked difference in the IFN-γ concentration pattern of PBMC of PV patients 
compared to that of healthy donors after stimulation with the synthetic peptides. In the case of 
healthy donors (D1, D2, D3) the IFN-γ concentration was generally under the threshold value 
(50 pg/mL ± 25 pg/mL) with few exceptions. We measured increased level of IFN-γ from 
PBMC culture of the healthy donor D1 after stimulation with Dsg3/189-205 and Dsg3/763-
777 peptides. Stimulation with Dsg3/210-222 and Dsg3/206-222 peptides resulted in higher 
IFN-γ concentration in case of donor D3 (Figure 4B). 
Peptides within Dsg3/189-205 series show ambiguous pattern of IFN-γ concentration values 
on PV patients (P1, P2, P3) PBMC cultures (Figure 4A): full length Dsg3/189-205 has no 
stimulatory effect on either of the patients’ PBMC; and only Dsg3/192-205 peptide resulted in 
IFN-γ concentration above the threshold with all PV patient donors’ cultures.  
Analyzing the IFN-γ concentration caused by stimulation with peptides from series Dsg3/206-
222 and Dsg3/342-358 we can summarize the following: donor P1’s IFN-γ levels were 
markedly above the threshold with Dsg3/206-222, Dsg3/208-222, and Dsg3/342-358, 
Dsg3/345-358, Dsg3/347-358 peptides (Figure 4A). In case of PV patient P2 two peptides 
showed similar effects: Dsg3/208-222 and Dsg3/210-222. On the other hand, truncated 
peptides within series Dsg3/342-358 had no effect, but the full length Dsg3/342-358 showed 
relatively high activity; although with high SD value. In case of PV patient P3 the peptides 
with the strongest stimulating activity were: Dsg3/206-222, Dsg3/342-358 and Dsg3/345-358. 
Dsg3/347-358 peptide has similar in vitro effect although also with high SD. 
The truncated derivatives of the full length Dsg3/761-777 peptide (Dsg3/763-777, Dsg3/764-
777 and Dsg3/766-777) were found to be the most unambiguous series: the determined IFN-γ 
was above the threshold for both P1 and P2 PV patients. In case of patient P3 we measured 
high IFN-γ concentration after the stimulation with Dsg3/764-777 and moderate value with 
Dsg3/763-777 peptide. The in vitro activity of the full length Dsg3/761-777 was not 
satisfactory. It is important to note, that the truncated peptides of this series were remarkably 
effective on PBMC cultures of PV patients, and at the same time they were almost inactive on 




Synthetic peptides are as efficient in inducing in vitro T-cell responses as recombinant 
proteins. The use of peptides represents an advantage as they do not require uptake and 
processing, and can be presented directly by the major histocompatibility complex (MHC, 
human leukocyte antigen (HLA) class I and II) molecules of antigen presenting cells like 
monocytes, B-lymphocytes and macrophages [26-28]. The naturally processed peptides enter 
the intracellular endosomal processing pathway in which the bulk of the de novo synthesized 
HLA molecules are loaded. By contrast, synthetic peptides have limited access to this 
dominant intracellular processing pathway, and rely instead for their presentation on a small 
number of recirculating cytoplasmic HLA molecules (after cellular uptake) or by peptide 
exchange occurring at the cell surface [69-73]. 
The in vitro applicability of synthetic peptides as antigens depends on their properties. 
Besides the primary structure a synthetic antigen has to be: (i) soluble in the cell culture 
medium, (ii) stable in the in vitro environment, (iii) non cytotoxic on isolated PBMC culture, 
and according to our hypothesis (iv) in aqueous environment their solution conformation 
should be relatively flexible for providing efficient T-cell stimulatory ability in vitro. Our 
Dsg3 peptide series have been investigated in view of the above listed requirements. To 
define suitable synthetic peptides or peptide series (peptide set) to fulfill these challenging 
criteria we performed a systematic study. In this paper we report the design, synthesis, 
chemical and conformational characterization, and in vitro evaluation of four 17mer peptides 
representing four Dsg3 T-cell epitope regions (Dsg3/189-205, Dsg3/206-222, Dsg3/342-358 
and Dsg3/761-777) and their N-terminally truncated derivatives (Dsg3/190-205, Dsg3/192-
205, Dsg3/194-205, Dsg3/208-222, Dsg3/210-222, Dsg3/343-358, Dsg3/345-358, Dsg3/347-
358, Dsg3/763-777, Dsg3/764-777, Dsg3/766-777).  
All of the synthetic peptides were stable under in vitro conditions. Most of the peptides were 
soluble in the RPMI-1640 cell culture medium. The solubility of the peptides, if necessary 
(e.g. Dsg3/342-358), might be improved by substitution with carefully selected amino acids to 
preserve in vitro activity. The results obtained from the MTT assay show that none of the 
synthetic peptides were cytotoxic in vitro (at the concentration range applied in PBMC 
stimulation experiments). 
The conformational features of the 17mer, full length peptides (Dsg3/189-205, Dsg3/206-222, 
Dsg3/342-358, Dsg3/761-777) and their N-terminally truncated derivatives were determined 
in solution using ECD spectroscopy following a Chou-Fasman secondary structure prediction 
analysis of the studied regions. We found that 17mer peptides Dsg3/206-222 and Dsg3/342-
358 and their truncated derivatives had stable ordered secondary structure in TFE and 
water/TFE solvent mixture, based on ECD data. These findings are in agreement of the results 
obtained from prediction analysis of the respective sequences: the propensity to form 
periodical ordered structures (α-helix or β-sheet) was calculated by the prediction algorithm. 
In 50% TFE/water we observed matching behavior: decreased helical content and increased 
unordered conformer ratio in the mixture of conformers. In water the unordered structures 
dominate in case of all peptides. The full length Dsg3/189-205 and Dsg3/761-777 peptides 
had less contribution of ordered structural elements featuring longer stretches of unordered 
regions according to the prediction analysis, reinforced fully in case of Dsg3/761-777 by ECD 
data. The Chou-Fasman prediction for these two regions shows mainly β-structures (beta-
sheet and isolated β-turns). 
The N-terminally truncated derivatives of Dsg3/189-205 peptide (namely, Dsg3/190-205, 
Dsg3/192-205) showed similar secondary structural elements to the full length Dsg3/189-205 
peptide (mainly α-helix), except the shortest Dsg3/194-205 (310 helix, with unordered and β-
sheet structures). In TFE-water in spite of the growth of the unordered elements, the intensity 
has not decreased radically. All truncated peptides adopted mostly unordered structure in 
water. The truncated derivatives of Dsg3/761-777 peptide have lower intensity ECD spectra 
in TFE than the other truncated peptide series, which observation indicates the lower ordered 
structure content: α-helical structure and unordered elements. The N-terminal truncation 
caused gradually smaller ordered structure content; the shortest peptide, Dsg3/766-777 
features typical C-type curve characteristics (isolated β-turn conformers like β-turn (I-III), 
together with unordered structure). In TFE-water mixture as well, the ratio of unordered 
conformers is much higher compared to any other peptide series. This fact suggests very low 
solvent resistance. These findings, suggesting the presence of isolated turns, are in good 
agreement with the Chou-Fasman analysis, which showed very high probability of turn 
structures for the Dsg3/761-777 region. Although all full length peptides show the prevalence 
of α-helix in the helix-promoting solvent TFE, and mostly in TFE/water mixture as well, the 
truncated peptide series have higher tendency to adopt β-structures (either β-turn or β-strand) 
besides the presence of α-helix. Comparing the four synthetic peptide series representing T-
cell epitope regions, Dsg3/761-777 series has a remarkably high instability regarding the 
ordered structure elements, and this solvent sensibility might suggest high backbone 
flexibility.  
The in vitro T-cell response differences (as IFN-γ level determined from supernatants of 
PBMC cultures) between healthy donors and PV patients can be detected using synthetic 
Dsg3 peptides as antigens. We would like to highlight the in vitro stimulatory activity of three 
peptides on all patients and healthy donors’ PBMC cultures: Dsg3/192-205, Dsg3/342-358 
and Dsg3/764-777. Following the stimulation with these synthetic peptide antigens we could 
distinguish the PV patients from healthy donors. Considering peptide series as antigen set 
instead of individual peptides, results with truncated peptides from Dsg3/761-777 series 
showed remarkable differences following stimulation of PBMC from PV and healthy donors.  
Comparing the in vitro activity with data from secondary structure analysis we would suggest 
that the solvent sensibility and high backbone flexibility of the synthetic peptides can be a 
considerable issue for differential in vitro PBMC stimulation ability. Overall, we can 
conclude that carefully chosen synthetic peptides or peptide series (set), with flexible 
secondary structure, can be appropriate antigens for differential in vitro T-cell stimulation for 
PV patients and healthy donors. Based on our results it is worth considering the combination 
of the following peptides as synthetic antigen set as an object for further study: Dsg3/192-205, 




 Figure legends 
Figure 1. Predicted secondary structural elements of the Dsg3 protein regions 189-205 (A), 
206-222 (B), 342-358 (C) and 761-777 (D) with 3 additional amino acid residues on both N- 
and C-termini in order to show the region in the relation of the intact protein. A sequential 
segment length of 7 amino acids was chosen. The probability value of the predicted secondary 
structural element for each segment was plotted at the position of the fourth residue.  
Figure 2. The ECD spectra of peptides Dsg3/189-205, Dsg3/206-222, Dsg3/342-358, and 
Dsg3/761-777 recorded in TFE (A), and water (B), full length Dsg3/761-777 peptide and its 
N-terminally truncated derivatives in TFE (C), full length Dsg3/761-777 peptide and its N-
terminally truncated derivatives in water/TFE (1:1, v/v) (D).  
Figure 3. Analytical RP-HPLC chromatogram of the RPMI-1640 incomplete medium and the 
Dsg3/761-777 peptide after 0 hour, 24 hours and 48 hours. Peak 4 represents the Dsg3/761-
777 peptide while peaks 1-3 and 5-10 are components of the RPMI-1640. 
Figure 4. Average IFN-γ concentration of 2-2 parallel measurements from supernatants of 
three PV patients (A) and three healthy donors (B) determined by ELISA after 20 hours of in 
vitro PBMC stimulation with 25 µM synthetic peptide. Filled symbols represent IFN-γ levels 
with maximum 25% standard deviation, while unfilled symbols represent uncertain IFN-γ 
levels where the standard deviation is higher than 25%. The threshold value (50 pg/ml IFN-γ) 
and the ± 25 pg/ml represented by grey horizontal area. The full length peptides are 
highlighted in frames.  
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